BRPI0812562A2 - composições terapêuticas anti-cd20 e métodos - Google Patents
composições terapêuticas anti-cd20 e métodosInfo
- Publication number
- BRPI0812562A2 BRPI0812562A2 BRPI0812562A BRPI0812562A BRPI0812562A2 BR PI0812562 A2 BRPI0812562 A2 BR PI0812562A2 BR PI0812562 A BRPI0812562 A BR PI0812562A BR PI0812562 A BRPI0812562 A BR PI0812562A BR PI0812562 A2 BRPI0812562 A2 BR PI0812562A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- therapeutic compositions
- therapeutic
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93434107P | 2007-06-12 | 2007-06-12 | |
| PCT/US2008/007464 WO2008156713A2 (en) | 2007-06-12 | 2008-06-12 | Anti-cd20 therapeutic compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0812562A2 true BRPI0812562A2 (pt) | 2019-09-24 |
Family
ID=39884723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0812562A BRPI0812562A2 (pt) | 2007-06-12 | 2008-06-12 | composições terapêuticas anti-cd20 e métodos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100330089A1 (pt) |
| EP (1) | EP2164871A2 (pt) |
| JP (1) | JP2010531137A (pt) |
| KR (1) | KR20100044160A (pt) |
| CN (1) | CN101842389A (pt) |
| AU (1) | AU2008266952A1 (pt) |
| BR (1) | BRPI0812562A2 (pt) |
| CA (1) | CA2691322A1 (pt) |
| CO (1) | CO6251370A2 (pt) |
| IL (1) | IL202684A0 (pt) |
| MX (1) | MX2009013656A (pt) |
| RU (1) | RU2010100638A (pt) |
| WO (1) | WO2008156713A2 (pt) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20151261T1 (hr) | 2007-07-02 | 2016-01-01 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka |
| RU2011124527A (ru) * | 2008-11-17 | 2012-12-27 | Дженентек, Инк. | Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях |
| RU2011137030A (ru) | 2009-03-11 | 2013-04-20 | УАЙТ ЭлЭлСи | Способы очистки малых модулярных иммунофармацевтических белков |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| DK3202898T3 (en) | 2009-11-02 | 2019-01-14 | Univ Washington | THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES |
| AR080155A1 (es) * | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos anti-cd20 y su utilizacion |
| US9173961B2 (en) * | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| PH12013502441B1 (en) | 2011-04-29 | 2019-02-08 | Univ Washington | Therapeutic nuclease compositions and methods |
| JP6185463B2 (ja) | 2011-07-15 | 2017-08-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ結合剤およびその使用法 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| TR201904882T4 (tr) * | 2011-11-17 | 2019-05-21 | Gundram Jung | Tıbbi kullanım için bispesifik antikorlar. |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS |
| WO2013109904A1 (en) * | 2012-01-19 | 2013-07-25 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| EA032038B1 (ru) | 2012-07-13 | 2019-03-29 | Онкомед Фармасьютикалс, Инк. | Rspo3-связывающие агенты и их применение |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| BR112016013741A2 (pt) * | 2013-12-17 | 2017-10-03 | Genentech Inc | Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| EP3180027A4 (en) * | 2014-08-15 | 2018-01-10 | Oncomed Pharmaceuticals, Inc. | Rspo1 binding agents and uses thereof |
| JP2017528523A (ja) | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| EP3221351B1 (en) | 2014-11-19 | 2024-11-13 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of epha2 |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| AU2017290389B2 (en) | 2016-07-01 | 2024-09-26 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| US10947295B2 (en) | 2017-08-22 | 2021-03-16 | Sanabio, Llc | Heterodimers of soluble interferon receptors and uses thereof |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047337A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| EP2295080A3 (en) * | 2005-07-25 | 2011-06-22 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| BRPI0614183A2 (pt) * | 2005-07-25 | 2011-03-15 | Trubion Pharmaceuticals Inc | uso de dose única de moléculas de ligação especìficas para cd20 |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
-
2008
- 2008-06-12 CN CN200880100872A patent/CN101842389A/zh active Pending
- 2008-06-12 KR KR1020107000237A patent/KR20100044160A/ko not_active Withdrawn
- 2008-06-12 BR BRPI0812562A patent/BRPI0812562A2/pt not_active IP Right Cessation
- 2008-06-12 EP EP08768486A patent/EP2164871A2/en not_active Withdrawn
- 2008-06-12 AU AU2008266952A patent/AU2008266952A1/en not_active Abandoned
- 2008-06-12 RU RU2010100638/10A patent/RU2010100638A/ru not_active Application Discontinuation
- 2008-06-12 MX MX2009013656A patent/MX2009013656A/es not_active Application Discontinuation
- 2008-06-12 WO PCT/US2008/007464 patent/WO2008156713A2/en not_active Ceased
- 2008-06-12 CA CA2691322A patent/CA2691322A1/en not_active Abandoned
- 2008-06-12 US US12/664,166 patent/US20100330089A1/en not_active Abandoned
- 2008-06-12 JP JP2010512214A patent/JP2010531137A/ja not_active Withdrawn
-
2009
- 2009-12-10 IL IL202684A patent/IL202684A0/en unknown
-
2010
- 2010-01-12 CO CO10002346A patent/CO6251370A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101842389A (zh) | 2010-09-22 |
| WO2008156713A3 (en) | 2009-05-28 |
| RU2010100638A (ru) | 2011-07-20 |
| WO2008156713A2 (en) | 2008-12-24 |
| MX2009013656A (es) | 2010-03-30 |
| CO6251370A2 (es) | 2011-02-21 |
| JP2010531137A (ja) | 2010-09-24 |
| CA2691322A1 (en) | 2008-12-24 |
| KR20100044160A (ko) | 2010-04-29 |
| US20100330089A1 (en) | 2010-12-30 |
| IL202684A0 (en) | 2011-08-01 |
| EP2164871A2 (en) | 2010-03-24 |
| AU2008266952A1 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301056I1 (nl) | Polatuzumab vedotin | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| IL202684A0 (en) | Anti-cd20 therapeutic compositions and methods of use thereof | |
| PT2356462T (pt) | Composições e métodos anti-cxcr1 | |
| BRPI0813647A2 (pt) | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| EP2241332A4 (en) | THERAPEUTIC AGENT AGAINST PRITURE | |
| DK2144905T3 (da) | Terapeutiske midler | |
| DK2035369T3 (da) | Terapeutiske | |
| DK2051606T3 (da) | Lænestol | |
| ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
| DK3300729T3 (da) | Terapeutiske sammensætninger indeholdende macitentan | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| EP2268281A4 (en) | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | |
| BRPI0807905A2 (pt) | Composições medicinais aperfeiçoadas compreendendo buprenorfina e naloxona. | |
| EP2185112A4 (en) | Stabilized therapeutic compositions and formulations | |
| EP2298365A4 (en) | MEDICAL COMPOSITION AND MEDICAL KIT | |
| BRPI0821351A2 (pt) | aparelhos e métodos | |
| EP2197448A4 (en) | dosing schedule | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| BRPI0812932A2 (pt) | Composições e métodos de tratar câncer | |
| BRPI0807903A2 (pt) | Composições medicinais melhoradas compreendendo buprenorfina e nalmefeno. | |
| BRPI0812000A2 (pt) | Métodos e composições para administração de oxibutinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |